Disc Medicine, Inc. (IRON) Earnings History

Disc Medicine, Inc. - Q4 FY2025 Earnings

Filed at: Feb 26, 2026, 8:32 AM EST|Read from source

EXECUTIVE SUMMARY

Disc Medicine reported its fourth quarter and full year 2025 financial results, highlighting significant progress in its clinical pipeline with key data presentations and study initiations. The company ended the year with a strong cash position, providing ample runway for future operations, while research and development expenses increased substantially to support pipeline advancement.

POSITIVE HIGHLIGHTS

  • •

    Strong cash position with approximately $791 million in cash, cash equivalents, and marketable securities as of December 31, 2025, providing runway into 2029.

    positive
  • •

    Initial data from Phase 2 study of DISC-0974 in patients with anemia of myelofibrosis (MF) presented at ASH conference demonstrated meaningful overall anemia responses.

    positive
  • •

    Progressing ongoing Phase 2 study of DISC-3405 in polycythemia vera (PV) and initiated a Phase 1b study of DISC-3405 in sickle cell disease (SCD) in Q4 2025.

    positive

CONCERNS & RISKS

  • •

    Received a Complete Response Letter (CRL) from the FDA in February 2026 related to sufficiency of evidence for bitopertin.

    negative
  • •

    Net loss increased to $212.2 million for the full year ended December 31, 2025, compared to $109.4 million in the prior year, primarily due to higher operating costs.

    negative
  • •

    Research and Development expenses increased significantly to $170.6 million for the full year ended December 31, 2025, from $96.7 million in the prior year.

    attention
  • •

    Selling, General and Administrative expenses increased to $65.4 million for the full year ended December 31, 2025, from $33.0 million in the prior year.

    attention

FINANCIAL METRICS

Revenue
Quarterly
N/A
N/A
Net Income
Quarterly
N/A
N/A
Annual (YTD)
$-212.18M
N/A
Prior year: $-109.36M
EPS (Diluted)
Quarterly
N/A
N/A
Annual (YTD)
$-6.01
N/A
Prior year: $-3.96
Operating Income
Quarterly
N/A
N/A
Annual (YTD)
$-236.02M
N/A
Prior year: $-129.72M
EPS (Basic)
Quarterly
N/A
N/A
Annual (YTD)
$-6.01
N/A
Prior year: $-3.96

MARGIN ANALYSIS

Margin metrics will be available once backend extracts data from insights_json

MANAGEMENT COMMENTARY

Confident in the bitopertin program and Phase 3 APOLLO study, committed to working with FDA for approval post-APOLLO.

— Disc Medicine, Inc., Q4 FY2025 2025 Earnings Call

Broader pipeline continues to deliver meaningful momentum with powerful data from DISC-0974 in MF anemia.

— Disc Medicine, Inc., Q4 FY2025 2025 Earnings Call

Excited about DISC-3405 with first in-patient data expected in both polycythemia vera and sickle cell disease later this year.

— Disc Medicine, Inc., Q4 FY2025 2025 Earnings Call

Commentary excerpts from earnings call transcripts provide management's perspective on performance, strategy, and outlook. Always review full transcripts for complete context.